Novo Nordisk A/S found using ticker (NVO) now have 3 analysts in total covering the stock. The consensus rating is ‘Strong_Buy’. The range between the high target price and low target price is between 132.54 and 118.16 with a mean TP of 126.24. With the stocks previous close at 99.22 this now indicates there is a potential upside of 27.2%. The 50 day MA is 107.75 and the 200 day MA is 107.59. The market cap for the company is $222,659m. You can visit the company’s website by visiting: https://www.novonordisk.com
The potential market cap would be $283,295m based on the market concensus.
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences Novo Nordisk A/S also has a research collaboration with Lumen Bioscience to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
